# Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

> **NCT02982720** · PHASE2 · TERMINATED · sponsor: **Aiwu Ruth He, MD** · enrollment: 4 (actual)

## Conditions studied

- Advanced Cholangiocarcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Sylatron

## Key facts

- **NCT ID:** NCT02982720
- **Lead sponsor:** Aiwu Ruth He, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-05
- **Primary completion:** 2018-02-09
- **Final completion:** 2018-02-09
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Manufacturer discontinued Sylatron
- **Last updated:** 2022-02-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982720, "Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02982720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*